A number of other research analysts have also issued reports on the stock. BidaskClub raised shares of Misonix from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 3rd. Zacks Investment Research lowered shares of ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $28.67.
ProQR Therapeutics stock opened at $9.07 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.08 and a quick ratio of 10.08. The firm’s 50-day moving average price is $10.58. The firm has a market cap of $310.60 million, a price-to-earnings ratio of -7.03 and a beta of 0.11. ProQR Therapeutics has a 52-week low of $6.40 and a 52-week high of $24.00.
Several large investors have recently modified their holdings of PRQR. Pura Vida Investments LLC lifted its stake in ProQR Therapeutics by 35.3% during the fourth quarter. Pura Vida Investments LLC now owns 76,827 shares of the biopharmaceutical company’s stock valued at $1,212,000 after purchasing an additional 20,024 shares during the last quarter. Northern Trust Corp acquired a new stake in ProQR Therapeutics during the fourth quarter valued at approximately $666,000. Nikko Asset Management Americas Inc. acquired a new stake in ProQR Therapeutics during the first quarter valued at approximately $4,016,000. Altrinsic Global Advisors LLC lifted its stake in ProQR Therapeutics by 9.8% during the first quarter. Altrinsic Global Advisors LLC now owns 199,060 shares of the biopharmaceutical company’s stock valued at $2,761,000 after purchasing an additional 17,700 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in ProQR Therapeutics by 14.1% during the fourth quarter. Geode Capital Management LLC now owns 19,193 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 2,375 shares during the last quarter. 61.75% of the stock is owned by institutional investors.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
See Also: What is a Lock-Up Period?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.